IRVINE, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Endocare, Inc. , an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation along with vacuum technologies for erectile dysfunction, announced today that new clinical data presented at the 91st Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) this week in Chicago demonstrates the effectiveness of cryoablation across a broad range of applications including the treatment of prostate and kidney cancer as well as tumors of the bone, liver, pelvis and lungs. More than 10 papers related to Endocare’s cryoablation technology were presented from the podium or in poster form at the conference.
Endocare Chairman and CEO Craig T. Davenport said that the range of applications where positive data are being collected indicates that this technology can be effective and durable in additional areas of interventional radiology and oncology medicine. “The fact that 12 leaders in interventional radiology are conducting research at some of the top cancer centers in the world is powerful evidence that a shift is occurring and that there is a new acceptance that cryoablation can emerge as an option for physicians and their patients,” said Davenport. “It is encouraging that thought leaders in the field of interventional radiology are applying our technology in so many ways outside of our traditional urology market. We believe this growing base of experience among physicians is due to unique benefits of using freezing temperatures to create lethal ice. However, while encouraging and promising, we still have much work to do before cryoablation becomes a mainstream treatment for these cancers.”
Highlighted publications or presentations at the meeting included several studies focusing on renal (kidney) cryoablation, including a Mayo Clinic-based study of the use of cryoablation for treatment of small renal masses; an update from an ongoing study first announced in March 2005 on focal cryoablation of the prostate, which aims at maintaining a man’s potency following the treatment; an exploration of the advantages of cryoablation to treat lesions of the musculoskeletal system over heat-based ablation modalities such as radiofrequency ablation; and an update from an ongoing study at the Mayo Clinic evaluating the effectiveness of cryoablation in treating painful metastatic tumors of the bone when other treatment modalities are not successful.
For the full abstracts on these and other studies presented at RSNA, please visit http://rsna2005.rsna.org/rsna2005/v2005/conference/track.cvn?id=6&p_navid=521 and search for the term cryoablation under the appropriate categories.
About Endocare
Endocare, Inc. -- www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation as well as vacuum technologies for erectile dysfunction. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung, liver and bone.
Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in “Risk Related to Our Business” in the Company’s Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to: uncertainty relating to ongoing investigations by governmental agencies; uncertainty regarding the effects of effectuating the proposed reverse stock split, in particular the possibility that the market may react negatively to our effectuation of a reverse stock split; uncertainty regarding market acceptance of the Company’s products; uncertainty of product development and the associated risks related to clinical trials; uncertainty relating to third party reimbursement; ability to convince health care professionals and third party payers of the medical and economic benefits of the Company’s products; difficulty in managing growth; the Company’s limited sales, marketing and manufacturing experience; ability to attract and retain key personnel; ability to secure and protect intellectual property rights relating to the Company’s technology; the rapid pace of technological change in the Company’s industry; fluctuations in the Company’s order levels; and the Company’s successful re-listing on a national stock exchange. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. We undertake no obligation to revise, or update publicly, any forward-looking statements for any reason.
Investor Contact: Media Contact: Matt Clawson Len Hall Allen & Caron, Inc. Allen & Caron, Inc. (949) 474-4300 (949) 474-4300 matt@allencaron.comlen@allencaron.comwww.allencaron.comwww.allencaron.com For Additional Information: Craig T. Davenport, CEO Michael R. Rodriguez, CFO Endocare, Inc. (949) 450-5400 www.endocare.com
Endocare, Inc.
CONTACT: investors, Matt Clawson, matt@allencaron.com, or media, Len Hall,len@allencaron.com, both of Allen & Caron, Inc., +1-949-474-4300, forEndocare, Inc.; or Craig T. Davenport, CEO, or Michael R. Rodriguez, CFO,both of Endocare, Inc., +1-949-450-5400
Web site: http://www.endocare.com//
